Genentech, Inc.
NEWS
The trial met its co-primary endpoints, showing statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared to standard-of-care, Bayer’s Nexavar.
Genentech’s flu medication Xofluza won a new indication for the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for less than 48 hours and are at high risk of flu-related complications.
What makes an organization a desirable employer? Do they need to be a large company with a recognizable name? Should the organization pay their employees more than others?
In the latest Ideal Employer Survey, BioSpace readers chimed in their thoughts on which companies across the biotech and biopharma industries were doing the most interesting and meaningful work.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
Researchers from Genentech and its parent company Roche have developed what is being called the first “deep learning model” that can predict which patients with diabetic retinopathy will progress the fastest.
50 million people worldwide live with symptomatic Alzheimer’s, which has no cure. In honor of September 21st being World Alzheimer’s Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
A stigma remains around lung cancer and many people still regard the disease as something of a self-inflicted ailment. But that stigma is waning, new research conducted by the Inova Schar Cancer Institute and Genentech shows.
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
JOBS
IN THE PRESS